Back to today’s briefing

Story perspectives

Metsera's Obesity Drug MET-233 Boosts Stock After Trial Success

6/9/2025

46 7

Summary

Story summary

Metsera, a New York startup, saw its stock soar over 8% following promising early trial results for its obesity drug, MET-233. Patients experienced weight loss of up to 8.4% in just 36 days. With its unique approach targeting amylin, MET-233 could challenge giants like Novo Nordisk and Eli Lilly, as Metsera gears up for more combination studies.

1 of 1

Story summary

Metsera, a New York startup, saw its stock soar over 8% following promising early trial results for its obesity drug, MET-233. Patients experienced weight loss of up to 8.4% in just 36 days. With its unique approach targeting amylin, MET-233 could challenge giants like Novo Nordisk and Eli Lilly, as Metsera gears up for more combination studies.